The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service

References

• Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009;28:287
   PubMedGoogle Scholar
• Irwin D, Milsom I, Hanskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Klotz T, Brüggenjürgen B, Burkart M, Resch A. The economic costs of overactive bladder in Germany. Eur Urol 2007;51:1654-63
   PubMed Web of Science ®Google Scholar
• Bohm K, Cordes M, Forster T, Krah K. Krankheitskosten 2002. Wiesbaden, Germany: Statistisches Bundesamt, 2004
   Google Scholar
• Basra R, Kellher C. A review of solifenacin in the treatment of urinary incontinence. Therapeut Clin Risk Manag 2008;4:117-28
   PubMedGoogle Scholar
• Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol 2011;202:319-44
   Google Scholar
• Andersson KE. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Therapeut Clin Risk Manag 2013;9:161-70
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003781
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU International 2012;11:1-8
   Google Scholar
• Chapple CR. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract 2010;64:1535-40
   PubMedGoogle Scholar
• Zinner NR, Dmochowski RR, Staskin DR, et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn 2011;30:1214-19
   PubMedGoogle Scholar
• Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 2009;43:283-95
   PubMed Web of Science ®Google Scholar
• Speakman M, Khullar V, Mundy A, et al. A cost–utility analysis of once daily solifeancin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24:2173-9
   PubMed Web of Science ®Google Scholar
• Milsom I, Axelsen S, Kulseng-Hansen S, et al. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstectricia et Gynecologica 2009;88:693-9
   PubMed Web of Science ®Google Scholar
• Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Managed Care Pharm 2002;5:343-52
   Google Scholar
• Hakkart L, Verboom P, Phillips R, et al. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009;41:293-8
   PubMedGoogle Scholar
• Ko Y, Malone D, Armstrong E. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006;26:1694-702
   PubMed Web of Science ®Google Scholar
• Klingler C, Shah SMB, Barron AJG, et al. Regulatory space and the contextual mediation of common functional pressures: analyzing the factors that led to the German Efficiency Frontier approach. Health Policy 2013;109:270-80
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008;71:449-54
   PubMed Web of Science ®Google Scholar
• Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU International 2010;106:506-14
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5 Pt 1):1919-24
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International 2004;93:303-10
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU International 2007;100:579-87
   PubMed Web of Science ®Google Scholar
• Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171(6 Pt 1):2311-15
   PubMed Web of Science ®Google Scholar
• Arlandis-Guzman S, Errando-Smet C, Trocio J, et al. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urology 2011;11:9-19
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodynam 1998;17:599-611
   PubMed Web of Science ®Google Scholar
• Data from various German sickness funds. Personal communication from Professor Axel Olaf Kern (University of Ravensburg). January 2012
   Google Scholar
• Neilson A, Sieper J, Deeg M. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology 2010;49:2122-34
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Kirchhoff T, Wolka D, et al. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis and etanercept failure. Eur J Health Econ 2010;11:95-104
   PubMed Web of Science ®Google Scholar
• Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health 2009;12(Suppl 1):S10-15
   PubMed Web of Science ®Google Scholar